West Ham schedule another medical as blockbuster terms agreed late on New Year’s Day
West Ham appear to be closing in on two attacking reinforcements, with another medical reportedly scheduled as their January business gathers pace.
According to Sky Sports, Gil Vicente striker Pablo completed a medical on Thursday after the Hammers reached an agreement for his transfer. The club are now pushing to register the 21-year-old in time for Saturday’s Premier League clash against Wolves.
However, Pablo may not be the only forward arriving at the London Stadium in the coming days.
Castellanos next in line for West Ham move
After securing a deal for Pablo, West Ham have reportedly turned their attention to Lazio forward Taty Castellanos in what could be a significant New Year’s Day move.
Sky Sports Germany journalist Florian Plettenberg revealed on January 1 that the Hammers have agreed a £25.3 million deal plus add-ons for the Argentine striker. A medical is said to be scheduled, with a long-term contract waiting for the 27-year-old should everything go to plan.
Can the duo rescue West Ham’s season?
West Ham’s urgency in the transfer market reflects their struggles in front of goal this season. The Hammers have scored just 21 league goals — the sixth-lowest tally in the Premier League — and currently sit 18th in the table, four points adrift of safety.
Pablo represents something of a gamble given his age, but his return of 10 goals in 13 Liga Portugal appearances this season suggests real promise. Castellanos, meanwhile, has contributed two goals and three assists in 11 Serie A outings this campaign, after scoring 10 league goals last season.
A change of environment could help reignite his scoring form, and together the pair may provide the firepower needed to lift West Ham out of trouble and close the gap on Nottingham Forest.
Supporters have long called for decisive action in the transfer market, and these moves suggest the club’s hierarchy is finally responding. Whether it proves enough to secure Premier League survival, however, remains to be seen.